(Erstwhile UTI Pharma & Healthcare Fund) Table of Contents The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR
return of 15% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . NAV as on 24 Mar 25 ₹272.897 ↑ 1.88 (0.69 %) Net Assets (AUM) as on 28 Feb 2025 ₹1,057 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 1.36 Expense Ratio 2.38 % Sharpe Ratio 0.28 Information Ratio -0.09 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 24 Mar 25 Duration Returns 1 Month 6.7% 3 Month -4.8% 6 Month -5.1% 1 Year 23.9% 3 Year 19.9% 5 Year 29.5% 10 Year 15 Year Since launch 15% Historical Annual Returns
Year Returns 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% 2015 -9.7% Growth of 10k Over Years
Date Value 29 Feb 20 ₹10,000 28 Feb 21 ₹15,607 28 Feb 22 ₹17,328 28 Feb 23 ₹16,427 29 Feb 24 ₹25,870 28 Feb 25 ₹28,711 Asset Allocation
Asset Class Value Cash 2.26% Equity 97.74% Sector Allocation
Sector Value Health Care 96.4% Basic Materials 1.35% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 11% ₹126 Cr 725,000 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 500087Drug Manufacturers - Specialty & Generic 6% ₹69 Cr 464,949 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 5% ₹57 Cr 470,234 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 532331Drug Manufacturers - Specialty & Generic 4% ₹50 Cr 186,798
↓ -6,249 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 532296Drug Manufacturers - Specialty & Generic 4% ₹45 Cr 309,311 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHLDrug Manufacturers - Specialty & Generic 3% ₹40 Cr 74,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 3% ₹38 Cr 56,271
↓ -3,729 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - Specialty & Generic 3% ₹37 Cr 240,477
↓ -25,829 Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Jun 21 | 543308Medical Care Facilities 3% ₹36 Cr 597,765 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 532843Medical Care Facilities 3% ₹36 Cr 557,701
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 2.83 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹272.897
↑ 1.88 -5.12 % 23.94 % 19.87 % 29.5 % UTI Healthcare Fund
Normal Dividend, Payout ₹210.911
↑ 1.45 -5.12 % 23.94 % 19.87 % 29.51 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹210.911
↑ 1.45 -5.12 % 23.94 % 19.87 % 29.51 % Data as on 24 Mar 25